Protocol Ledger

NCT06037889 · Phase III · COMPLETED

Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)

Interventional Phase III clinical trial protocol NCT06037889 sponsored by Peking Union Medical College Hospital in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-11-09 Enrollment: 516 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06037889
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)516 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06037889
Protocol FieldVerified Registry Value
NCT IdentifierNCT06037889
Consolidated Lead SponsorPeking Union Medical College Hospital
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment516 participants (ACTUAL)
Registered Start Date2023-11-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06037889
Hospital Research SiteLocationSite Profile
Peking Union Medical College HospitalBeijing, ChinaOpen Hospital Dossier ->
Xuzhou central HospitalXuzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI